Generic Akeega Availability
Last updated on Apr 10, 2025.
Akeega is a brand name of abiraterone/niraparib, approved by the FDA in the following formulation(s):
AKEEGA (abiraterone acetate; niraparib tosylate - tablet;oral)
-
Manufacturer: JANSSEN BIOTECH
Approval date: August 11, 2023
Strength(s): 500MG;EQ 50MG BASE [RLD], 500MG;EQ 100MG BASE [RLD]
Is there a generic version of Akeega available?
No. There is currently no therapeutically equivalent version of Akeega available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Akeega. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Niraparib compositions
Patent 11,091,459
Issued: August 17, 2021
Inventor(s): Wu; George et al.
Assignee(s): Tesaro, Inc. (Waltham, MA); Merck Sharp & Dohme Corp. (Rahway, NJ)The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
Patent expiration dates:
- March 27, 2038✓✓
- March 27, 2038
-
Method of treating prostate cancer
Patent 11,207,311
Issued: December 28, 2021
Inventor(s): Gottardis Marco & Hawkins Rebecca & Snyder Linda A & Yamada Douglas H
Assignee(s): Janssen Pharmaceutica NVDisclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
Patent expiration dates:
- July 28, 2037✓
- July 28, 2037
-
Niraparib compositions
Patent 11,673,877
Issued: June 13, 2023
Inventor(s): Wu; George et al.
Assignee(s): Tesaro, Inc. (Wilmington, DE); Merck Sharp & Dohme Corp. (Rahway, NJ)The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
Patent expiration dates:
- March 27, 2038✓✓
- March 27, 2038
-
Methods of treating prostate cancer
Patent 11,986,468
Issued: May 21, 2024
Inventor(s): Gottardis; Marco et al.
Assignee(s): Janssen Pharmaceutica NV (Beerse, BE)Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
Patent expiration dates:
- July 28, 2037✓
- July 28, 2037
-
Methods of treating prostate cancer
Patent 11,986,469
Issued: May 21, 2024
Inventor(s): Gottardis; Marco et al.
Assignee(s): Janssen Pharmaceutica NV (Beerse, BE)Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
Patent expiration dates:
- July 28, 2037✓
- July 28, 2037
-
Methods of treating prostate cancer
Patent 11,992,486
Issued: May 28, 2024
Inventor(s): Gottardis; Marco et al.
Assignee(s): Janssen Pharmaceutica NV (Beerse, BE)Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.
Patent expiration dates:
- July 28, 2037✓
- July 28, 2037
-
DNA damage repair inhibitors for the treatment of cancer
Patent 8,071,579
Issued: December 6, 2011
Inventor(s): Ashworth; Alan et al.
Assignee(s): The Institute of Cancer Research: Royal Cancer Hospital (London, GB); Kudos Pharmaceuticals Limited (Cambridge, GB)The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Patent expiration dates:
- August 12, 2027✓
- August 12, 2027
-
Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Patent 8,071,623
Issued: December 6, 2011
Inventor(s): Jones; Philip et al.
Assignee(s): Instituto di Ricerche di Biologia Molecolare P. Angeletti SpA (Rome, unknown)The present invention relates to compounds of formula I: ##STR00001## and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- and/or radiosensitizers for cancer treatment.
Patent expiration dates:
- March 27, 2031✓✓
- March 27, 2031
-
DNA damage repair inhibitors for treatment of cancer
Patent 8,143,241
Issued: March 27, 2012
Inventor(s): Ashworth; Alan et al.
Assignee(s): Kudos Pharmaceuticals Limited (Cambridge, GB); The Institute of Cancer Research (London, GB)The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Patent expiration dates:
- August 12, 2027✓
- August 12, 2027
-
[S, H]
Patent 8,436,185
Issued: May 7, 2013
Inventor(s): Foley Jennifer R. & Wilson Robert Darrin
Assignee(s): Merck Sharp & Dohme Corp.The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl) transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA-damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.
Patent expiration dates:
- April 24, 2029✓✓
- April 24, 2029
-
Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Patent 8,859,562
Issued: October 14, 2014
Inventor(s): Helleday Thomas
Assignee(s): The University of SheffieldThe present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.
Patent expiration dates:
- August 4, 2031✓
- August 4, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 11, 2026 - NEW PRODUCT
More about Akeega (abiraterone / niraparib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antineoplastic combinations
- En español
Patient resources
Professional resources
- Akeega prescribing information
- Niraparib Tosylate Monohydrate and Abiraterone Acetate (AHFS Monograph)
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.